Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) Short Interest Update

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 216,200 shares, a growth of 601.9% from the January 31st total of 30,800 shares. Based on an average daily volume of 2,130,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 24.0% of the company’s stock are sold short.

Institutional Trading of Lipella Pharmaceuticals

A hedge fund recently bought a new stake in Lipella Pharmaceuticals stock. Virtu Financial LLC acquired a new position in shares of Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 13,310 shares of the company’s stock, valued at approximately $41,000. Virtu Financial LLC owned approximately 1.10% of Lipella Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 74.31% of the company’s stock.

Lipella Pharmaceuticals Stock Down 7.8 %

Shares of LIPO opened at $2.94 on Friday. Lipella Pharmaceuticals has a 52-week low of $2.21 and a 52-week high of $12.00. The firm has a market cap of $3.55 million, a price-to-earnings ratio of -0.69 and a beta of 0.28. The business’s 50 day moving average is $3.16 and its two-hundred day moving average is $3.18.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).